About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNPhase 2/3NCT00387972

Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)

GW823093 is a selective DPP-IV Inhibitor and is being investigated as a once a day oral therapy. The purpose of the Study is to evaluate the effectiveness, safety, and tolerability of 2 doses of GW823...

Lead sponsor: GlaxoSmithKline•57 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

GlaxoSmithKline

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment
•Body mass index between 20 and 40
•Females of childbearing potential must use adequate birth control.

Exclusion Criteria

•Subjects with previous use of insulin
•Type 1 diabetes
•Uncontrolled thyroid disease
•History of drug or alcohol abuse in the past year
•Any other clinically significant disease.

Related studies

RECRUITINGPhase 4

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT06613854 · Type 2 Diabetes Mellitus (T2DM)

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

NCT07232537 · Chronic Kidney Disease, Type 2 Diabetes Mellitus

An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

NCT06278207 · Chronic Kidney Disease, Type 2 Diabetes Mellitus

Polyphenol Metabotypes in People With Diabetes Type 2

NCT06810635 · Type 2 Diabetes Mellitus (T2DM)

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005 · Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 17, 2015Terms

Trial snapshot

StatusWITHDRAWN

PhasePHASE2/PHASE3

Enrollment—

Start dateMay 2006

Last updatedApr 17, 2015

Condition

Type 2 Diabetes Mellitus

Locations shown

GSK Clinical Trials Call Center

Tallassee, Alabama

GSK Clinical Trials Call Center

Phoenix, Arizona

GSK Clinical Trials Call Center

Tucson, Arizona

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 17, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions